Adaptive Biotechnologies Terminates Material Agreement
Ticker: ADPT · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1478320
| Field | Detail |
|---|---|
| Company | Adaptive Biotechnologies Corp (ADPT) |
| Form Type | 8-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $33.7 million, $25, $30 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement-termination, 8-k
TL;DR
Adaptive Bio terminates major deal, investors watch closely.
AI Summary
Adaptive Biotechnologies Corporation announced on August 13, 2025, the termination of a material definitive agreement. The company, incorporated in Washington, filed this 8-K report on August 18, 2025, detailing the event.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, partnerships, and financial standing, requiring close monitoring by investors.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement can signal underlying issues or strategic shifts that may affect the company's future performance.
Key Numbers
- 001-38957 — SEC File Number (Identifies the company's filing with the SEC.)
- 27-0907024 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Adaptive Biotechnologies Corporation (company) — Registrant
- August 13, 2025 (date) — Date of earliest event reported
- August 18, 2025 (date) — Filing date
- Washington (location) — State of incorporation
FAQ
What specific material definitive agreement was terminated?
The filing states the termination of a material definitive agreement but does not specify which agreement in the provided text.
When did the termination of the agreement become effective?
The filing indicates August 13, 2025, as the date of the earliest event reported, which is likely the effective date of the termination.
What are the implications of this termination for Adaptive Biotechnologies?
The filing does not detail the specific implications of the termination; further information would be needed to assess the impact.
Was this termination a mutual decision or initiated by one party?
The provided text does not specify whether the termination was mutual or unilateral.
Does this termination affect any ongoing research or product development?
The filing does not provide details on the impact on research or product development.
Filing Stats: 525 words · 2 min read · ~2 pages · Grade level 14.9 · Accepted 2025-08-18 08:00:37
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share ADPT The Nasdaq Stock Mar
- $33.7 million — mination, Adaptive expects to recognize $33.7 million during the second half of 2025 in non-c
- $25 — 025 Immune Medicine cash burn target of $25–$30 million. SIGNATURES Pursuant to
- $30 million — Immune Medicine cash burn target of $25–$30 million. SIGNATURES Pursuant to the require
Filing Documents
- d59058d8k.htm (8-K) — 23KB
- 0001193125-25-182222.txt ( ) — 130KB
- adpt-20250813.xsd (EX-101.SCH) — 3KB
- adpt-20250813_lab.xml (EX-101.LAB) — 17KB
- adpt-20250813_pre.xml (EX-101.PRE) — 11KB
- d59058d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Adaptive Biotechnologies Corporation Date: August 18, 2025 By: /s/ Kyle Piskel Kyle Piskel Chief Financial Officer